Takeda Pharmaceutical (NYSE:TAK - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 3.180-3.180 for the period. The company issued revenue guidance of $29.7 billion-$29.7 billion.
Takeda Pharmaceutical Stock Up 0.6 %
Shares of Takeda Pharmaceutical stock traded up $0.09 during trading hours on Friday, reaching $14.36. 4,353,385 shares of the company were exchanged, compared to its average volume of 1,889,107. The firm has a market cap of $45.69 billion, a PE ratio of 35.90, a PEG ratio of 0.24 and a beta of 0.26. The stock's fifty day moving average is $14.87 and its 200 day moving average is $14.00. Takeda Pharmaceutical has a 1 year low of $12.58 and a 1 year high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The company had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. As a group, equities research analysts forecast that Takeda Pharmaceutical will post 1.64 earnings per share for the current year.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.
Read Our Latest Stock Report on Takeda Pharmaceutical
Takeda Pharmaceutical Company Profile
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Featured Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
